WS #1341

The geopolitical crisis in the Middle East has intensified with new escalations, while corporate developments show mixed signals. A projectile strike near Iran's Bushehr nuclear power plant (items 10, 32) confirms earlier reports and represents a direct threat to nuclear infrastructure, heightening regional tensions. This is corroborated by Iran's Speaker of Parliament stating the Strait of Hormuz will not return to pre-war status (item 12), suggesting prolonged disruption to oil shipping routes that could sustain elevated oil prices. However, Polymarket data shows uncertainty about conflict resolution by March 31 (items 7, 8), indicating market skepticism about near-term de-escalation. In corporate news, Amazon's CEO reaffirmed projections that AI will double AWS sales to $600 billion by 2036 (items 21, 22), providing a strong bullish signal for AMZN and the AI sector. This contrasts with a large dark pool sale of NVDA shares mentioned previously, though NVDA shows slight declines in real-time quotes. Pfizer shares are trading higher after positive Phase 2 trial results and an upgraded price target (item 6), while SoFi Technologies faces pressure from a Muddy Waters short report (item 15). Vaccine stocks continue to rally after a Massachusetts judge blocked parts of RFK Jr.'s vaccine policy (item 36), offsetting healthcare sector concerns. Other developments include Unilever considering separation of its food assets (items 13, 16, 17), which could create value through restructuring. The meningitis outbreak in the UK remains a concern with questions about response timing (items 34, 35), though it appears contained regionally. Price context shows minor declines in major tech stocks (AAPL, MSFT, NVDA down 0.1-0.25%) and indices (SPY, QQQ down ~0.1%), while AMZN shows slight gains (0.10%) on high volume, reflecting the AWS news.